Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Lymphoma 53Lymphoma, Non-Hodgkin 36Lymphoma, Large B-Cell, Diffuse 34Lymphoma, Follicular 28Lymphoma, Mantle-Cell 26Glioblastoma 25Central Nervous System Neoplasms 25Hodgkin Disease 22Gliosarcoma 21Astrocytoma 21Lymphoma, Large-Cell, Immunoblastic 20Brain Neoplasms 20Burkitt Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 17Multiple Myeloma 15Glioma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Oligodendroglioma 12Lymphoma, B-Cell, Marginal Zone 11Leukemia 10Neoplasms, Plasma Cell 9Recurrence 7Lymphoma, B-Cell 5Waldenstrom Macroglobulinemia 4Medulloblastoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, T-Cell 4Leukemia, Myeloid, Acute 4Ependymoma 4Lymphoma, Large-Cell, Anaplastic 3

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Melanoma × Carmustine × Clear all
NCT00003346 2013-06-25

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
80 enrolled
Dermatologic

Melanoma

NCT00005961 2013-02-11

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡